Sotera Health vs Viemed Healthcare
SHC and VMD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SHC and VMD compare
Sotera Health is the larger company, worth 14 times as much as Viemed Healthcare ($5.2B against $368M).
On earnings, Viemed Healthcare is cheaper: it trades at 26.9× trailing earnings, against 31.8× for Sotera Health.
Viemed Healthcare grew revenue faster over the last twelve months (25.2% versus 8.1% for Sotera Health).
Sotera Health keeps more of each dollar of sales as profit, with a net margin of 13.4% compared with 4.8% at Viemed Healthcare.
Viemed Healthcare scores higher on the StockData Score (17 against 8 for Sotera Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SHC | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $5.2B | $368M |
| Share price | $18.15 | $9.67 |
| Change, 1 year | 9.5% | 47.9% |
| Change, 5 years | −32.7% | 59.0% |
| Beta (5Y) | 1.58 | 0.57 |
| Employees | 3,000 | 1,382 |
| StockData Score | ||
| Total score | 8 | 17 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 2 | 5 (better) |
| Performance score | 3 | 3 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 31.8× | 26.9× (better) |
| P/S | 4.3× | 1.2× (better) |
| P/B | 7.8× | 2.6× (better) |
| EV/EBITDA | – | 9.5× |
| P/FCF | 46.0× | 12.6× (better) |
| PEG | – | 0.83 |
| FCF yield | 2.2% | 7.9% (better) |
| Fair value | – | $10.78 |
| Margin of safety | – | 10.3% |
| Growth | ||
| Revenue growth (TTM) | 8.1% | 25.2% (better) |
| Revenue growth, 5Y average | 7.3% | 15.5% (better) |
| Net income growth (TTM) | 581% (better) | 3.7% |
| EPS growth (TTM) | 613% (better) | 5.9% |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | 55.0% | 57.5% (better) |
| Operating margin | – | 7.5% |
| Net margin | 13.4% (better) | 4.8% |
| FCF margin | 9.3% | 9.7% (better) |
| Return on equity | 27.8% (better) | 10.2% |
| Return on invested capital | – | 12.2% |
| Financial health | ||
| Debt / equity | 3.21 | 0.05 (better) |
| Net debt / EBITDA | – | −0.09 |
| Current ratio | 2.80 (better) | 1.13 |
| Altman Z-score | 1.50 | 6.42 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | 5.0% |
| Shareholder yield | 0.00% | 5.0% (better) |
| Ownership | ||
| Held by institutions | 103% | 71.3% |
| Held by insiders | – | 15.4% |
| Insider net buying, 12 months | −$2.6B | −$1.6M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 4.9% |
Go deeper
- SHC stock overview
- SHC income statement
- SHC valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.